- Published at
- by manilatimes.net
mixed
mixed
News for Aytu Biopharma, Inc. (AYTU)
- Published at
- by gurufocus.com
positivepositiveAytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic Growth Amid Challenges
Release Date: February 12, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aytu BioPhar- Published at
- by gurufocus.com
neutralneutralQ2 2025 Aytu Biopharma Inc Earnings Call Transcript
Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAYTU.OQ - Aytu Biopharma IncQ2 2025 Aytu Biopharma Inc Earnings CallFeb 12, 2025 / 09:30PM GMT- Published at
- by gurufocus.com
neutralneutralAytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase fo- Published at
- by seekingalpha.com
positivepositiveAytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings (NASDAQ:AYTU)
Earnings Call Insights: Aytu BioPharma (NASDAQ:AYTU) Q2 2025Management ViewCEO Josh Disbrow reported that both the ADHD and pediatric portfolios achieved...- Published at
- by seekingalpha.com
positivepositiveAytu BioPharma, Inc. (AYTU) Q2 2025 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ETCompany ParticipantsRobert Blum - Investor Relations, Lytham...- Published at
- by gurufocus.com
positivepositive- Published at
- by gurufocus.com
positivepositiveAytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing no- Published at
- by gurufocus.com
positivepositiveAchieve Life Sciences Appoints Mark Oki as Chief Financial Officer
SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ( ACHV), a late-stage pharmaceutical company dedicated- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveAytu BioPharma Disclosure Notification
DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIE- Published at
- by gurufocus.com
positivepositiveAytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing- Published at
- by seekingalpha.com
positivepositiveAytu BioPharma, Inc. (AYTU) Q1 2025 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsRobert Blum - IR, Lytham PartnersJosh...- Published at
- by gurufocus.com
positivepositiveIronwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive Analyst Recommendations
Ironwood Pharmaceuticals (IRWD) experienced a notable stock surge with shares rising by 5.01%. The stock was last reported at $4.40 per share with a trading vol- Published at
- by investing.com
mixedmixedAytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges- Published at
- by globenewswire.com
mixedmixedGlobal Over-The-Counter (OTC) Drugs Market Size Projected to Reach USD 149.72 Billion by 2032 with a 6.18% CAGR – SNS Insider
According to Research by SNS Insider, Over-The-Counter (OTC) Drugs Market Growth is Driven by Rising Consumer Awareness, Growth of Lifestyle Diseases, and...- Published at
- by investing.com
positivepositiveEarnings call: Aytu BioPharma reports turnaround with focus on ADHD By Investing.com
Earnings call: Aytu BioPharma reports turnaround with focus on ADHD- Published at
- by investing.com
positivepositiveEarnings call: Aytu BioPharma sees revenue growth, shifts focus to ADHD By Investing.com
Earnings call: Aytu BioPharma sees revenue growth, shifts focus to ADHD- Published at
- by globenewswire.com
mixedmixedPresenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging...- Published at
- by investing.com
positivepositiveEarnings call: Aytu BioPharma achieves first positive operating income By Investing.com
Earnings call: Aytu BioPharma achieves first positive operating income